BarH-Like Homeobox 2 Suppresses Cell Proliferation, Invasion, and Angiogenesis in Hepatocellular Carcinoma by Activating N-Acetylgalactosaminyltransferase 4.
Angiogenesis
BarH-like homeobox 2
Hepatocellular carcinoma
Invasion
N-acetylgalactosaminyltransferase 4
Journal
Molecular biotechnology
ISSN: 1559-0305
Titre abrégé: Mol Biotechnol
Pays: Switzerland
ID NLM: 9423533
Informations de publication
Date de publication:
13 Nov 2023
13 Nov 2023
Historique:
received:
16
03
2023
accepted:
05
10
2023
medline:
13
11
2023
pubmed:
13
11
2023
entrez:
13
11
2023
Statut:
aheadofprint
Résumé
BarH-like homeobox 2 (BARX2) has been identified to play a key role in the development of multiple cancers. Meanwhile, BARX2 may be an independent prognostic biomarker for patients suffering from hepatocellular carcinoma (HCC). Nevertheless, the regulatory role of BARX2 in HCC is still unclear and needs to be unveiled. In this study, the expressions of BARX2 and N-acetylgalactosaminyltransferase 4 (GALNT4) were evaluated by quantitative real-time PCR (qRT-PCR) as well as western blot. Besides, the abilities of cells to proliferate, migrate, invade, and angiogenesis were assessed with CCK-8, colony formation, wound-healing, Transwell, and tube formation assays, separately. Cell apoptosis was determined by flow cytometry analysis. The binding relationship between BARX2 and GALNT4 was predicted by JASPAR website and verified using Chromatin immunoprecipitation (ChIP) and luciferase report assay. It was discovered that BARX2 was reduced in HCC cell lines, while its overexpression greatly repressed cell proliferation, migration, invasion, and angiogenesis and promoted cell apoptosis in HuH7 and MHCC97-H cells. BARX2 could bind to GALNT4 promoter and positively regulate GALNT4 expression. In addition, GALNT4 deficiency partly abolished the inhibitory effects of BARX2 on the progression of HCC. In summary, this study highlights that BARX2 may hold promise for serving as a potential therapeutic target, facilitating the development of a novel therapeutic strategy against HCC.
Identifiants
pubmed: 37955776
doi: 10.1007/s12033-023-00930-9
pii: 10.1007/s12033-023-00930-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 81760439
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424.
pubmed: 30207593
Scheau, A. E., Scheau, C., & Lupescu, I. G. (2017). Nodule-in-nodule imaging pattern in hepatocellular carcinoma treated by transarterial chemoembolization: A multiparametric magnetic resonance imaging study. Journal of Gastrointestinal and Liver Diseases, 26(4), 387–393.
doi: 10.15403/jgld.2014.1121.264.nin
pubmed: 29253054
Yarchoan, M., Agarwal, P., Villanueva, A., Rao, S., Dawson, L. A., Llovet, J. M., et al. (2019). Recent developments and therapeutic strategies against hepatocellular carcinoma. Cancer Research, 79(17), 4326–4330.
doi: 10.1158/0008-5472.CAN-19-0803
pubmed: 31481419
pmcid: 8330805
Scheau, C., Badarau, I. A., Caruntu, C., Mihai, G. L., Didilescu, A. C., Constantin, C., Mihai, G. L., Didilescu, A. C., Constantin, C., & Neagu, M. (2019). Capsaicin: Effects on the pathogenesis of hepatocellular carcinoma. Molecules, 24(13), 2350.
doi: 10.3390/molecules24132350
pubmed: 31247901
pmcid: 6651067
Bhatia, R., Ravulapati, S., Befeler, A., Dombrowski, J., Gadani, S., & Poddar, N. (2017). Hepatocellular carcinoma with bone metastases: Incidence, prognostic significance, and management-single-center experience. Journal of Gastrointestinal Cancer, 48(4), 321–325.
doi: 10.1007/s12029-017-9998-6
pubmed: 28891006
Stevens, T. A., Iacovoni, J. S., Edelman, D. B., & Meech, R. (2004). Identification of novel binding elements and gene targets for the homeodomain protein BARX2. Journal of Biological Chemistry, 279(15), 14520–14530.
doi: 10.1074/jbc.M310259200
pubmed: 14744868
Chen, H., Zhang, M., Zhang, W., Li, Y., Zhu, J., Zhang, X., et al. (2018). Downregulation of BarH-like homeobox 2 promotes cell proliferation, migration and aerobic glycolysis through Wnt/beta-catenin signaling, and predicts a poor prognosis in non-small cell lung carcinoma. Thorac Cancer, 9(3), 390–399.
doi: 10.1111/1759-7714.12593
pubmed: 29341468
pmcid: 5832481
Yang, F., Shao, C., Wei, K., Jing, X., Qin, Z., Shi, Y., et al. (2019). miR-942 promotes tumor migration, invasion, and angiogenesis by regulating EMT via BARX2 in non-small-cell lung cancer. Journal of Cellular Physiology, 234(12), 23596–23607.
doi: 10.1002/jcp.28928
pubmed: 31236953
Mi, Y., Zhao, S., Zhang, W., Zhang, D., Weng, J., Huang, K., et al. (2016). Down-regulation of Barx2 predicts poor survival in colorectal cancer. Biochemical and Biophysical Research Communications, 478(1), 67–73.
doi: 10.1016/j.bbrc.2016.07.091
pubmed: 27453340
Mi, Y., Zhao, S., Zhou, C., Weng, J., Li, J., Wang, Z., et al. (2016). Downregulation of homeobox gene Barx2 increases gastric cancer proliferation and metastasis and predicts poor patient outcomes. Oncotarget, 7(37), 60593–60608.
doi: 10.18632/oncotarget.11260
pubmed: 27533254
pmcid: 5312404
Zhang, Y., Zhang, J. X., Huang, L. L., He, L. J., Liao, Y. J., Lai, Y. R., et al. (2015). Low expression of BARX2 in human primary hepatocellular carcinoma correlates with metastasis and predicts poor prognosis. Hepatology Research, 45(2), 228–237.
doi: 10.1111/hepr.12340
pubmed: 24716715
Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25(4), 402–408.
doi: 10.1006/meth.2001.1262
pubmed: 11846609
Xu, Q., Liu, Z., Zhu, Z. Q., Fan, Y., Chen, R., Xie, X. H., et al. (2021). Knockdown of growth factor receptor bound protein 7 suppresses angiogenesis by inhibiting the secretion of vascular endothelial growth factor A in ovarian cancer cells. Bioengineered, 12(2), 12179–12190.
doi: 10.1080/21655979.2021.2005225
pubmed: 34783299
pmcid: 8809950
Guan, H., Sun, C., Gu, Y., Li, J., Ji, J., & Zhu, Y. (2021). Circular RNA circ_0003028 contributes to tumorigenesis by regulating GOT2 via miR-1298-5p in non-small cell lung cancer. Bioengineered, 12(1), 2326–2340.
doi: 10.1080/21655979.2021.1935064
pubmed: 34077306
pmcid: 8806680
He, S., Zhang, W., Li, X., Wang, J., Chen, X., Chen, Y., et al. (2021). Oral squamous cell carcinoma (OSCC)-derived exosomal MiR-221 targets and regulates phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) to promote human umbilical vein endothelial cells migration and tube formation. Bioengineered, 12(1), 2164–2174.
doi: 10.1080/21655979.2021.1932222
pubmed: 34098850
pmcid: 8806445
Chen, W., Wang, H., Liu, J., & Li, K. (2022). Interference of KLF9 relieved the development of gestational diabetes mellitus by upregulating DDAH2. Bioengineered, 13(1), 395–406.
doi: 10.1080/21655979.2021.2005929
pubmed: 34787071
Wang, M., Yan, J., Cao, X., Hua, P., & Li, Z. (2020). Hydrogen sulfide modulates epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via HIF-1alpha activation. Biochemical Pharmacology, 172, 113775.
doi: 10.1016/j.bcp.2019.113775
pubmed: 31870768
Morse, M. A., Sun, W., Kim, R., He, A. R., Abada, P. B., Mynderse, M., et al. (2019). The role of angiogenesis in hepatocellular carcinoma. Clinical Cancer Research, 25(3), 912–920.
doi: 10.1158/1078-0432.CCR-18-1254
pubmed: 30274981
Niang, B., Jin, L., Chen, X., Guo, X., Zhang, H., Wu, Q., et al. (2016). GalNAc-T4 putatively modulates the estrogen regulatory network through FOXA1 glycosylation in human breast cancer cells. Molecular and Cellular Biochemistry, 411(1–2), 393–402.
doi: 10.1007/s11010-015-2601-1
pubmed: 26541755
Yan, X., Lu, J., Zou, X., Zhang, S., Cui, Y., Zhou, L., et al. (2018). The polypeptide N-acetylgalactosaminyltransferase 4 exhibits stage-dependent expression in colorectal cancer and affects tumorigenesis, invasion and differentiation. FEBS Journal, 285(16), 3041–3055.
doi: 10.1111/febs.14593
pubmed: 29931806
Weng, L., Ma, J., Jia, Y. P., Wu, S. Q., Liu, B. Y., Cao, Y., et al. (2018). MiR-4262 promotes cell apoptosis and inhibits proliferation of colon cancer cells: Involvement of GALNT4. American Journal of Translational Research, 10(12), 3969–3977.
pubmed: 30662643
pmcid: 6325503
Liu, Y., Liu, H., Yang, L., Wu, Q., Liu, W., Fu, Q., et al. (2017). Loss of N-acetylgalactosaminyltransferase-4 orchestrates oncogenic MicroRNA-9 in hepatocellular carcinoma. Journal of Biological Chemistry, 292(8), 3186–3200.
doi: 10.1074/jbc.M116.751685
pubmed: 28062574
pmcid: 5336155
Hu, C. Y., You, P., Zhang, J., Zhang, H., & Jiang, N. (2019). MiR-506-3p acts as a novel tumor suppressor in prostate cancer through targeting GALNT4. European Review for Medical and Pharmacological Sciences, 23(12), 5133–5138.
pubmed: 31298366
Xing, L., Hong, X., Chang, L., Ren, P., & Zhang, H. (2020). miR-365b regulates the development of non-small cell lung cancer via GALNT4. Experimental and Therapeutic Medicine, 20(2), 1637–1643.
doi: 10.3892/etm.2020.8857
pubmed: 32765677
pmcid: 7388555